Edward White

H.C. Wainwright & Co.

Edward P. White is the managing director, senior biotechnology analyst, at H.C. Wainwright & Co., where his research coverage focus is on small to mid-cap life sciences companies. He formerly was a senior biotech equity research analyst at FBR & Co. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.

Recent Articles about Syndax Pharmaceuticals Inc.

Trial of New Drug for Acute Leukemia Meets Primary Endpoint 10/05/2023

The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report.